Business
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China businessten largest-selling medicines grew by combined 4% and represented 33% of net sales Europe net sales grew by 7%[1]. International declined by 2%[1] and inc
About this update from Sandoz Group Ltd
[{"type":"image","alt":"Sandoz Group","displaySize":"","headline":null,"caption":"Sandoz Group","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qaCYsKqoASJVSMd1vUCp9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f12e92daa0852ddf107832c313b07d25","width":300,"height":41}},"lazy":false},{"type":"text","content":"Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules","length":72,"tagName":"p"},{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 2025 net sales of USD 2,480 million","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"up by 3% in constant currencies (cc); stable in USD","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"up by 5%[1] at a comparable growth rate (CGR), when adjusted for impact of 2024 acquisition of US biosimilar Cimerli® (ranibizumab) and 2024 divestment of China business","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"ten largest-selling medicines grew by combined 4% and represented 33% of net sales","length":82,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":302,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":340,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Europe net sales grew by 7%[1]. International declined by 2%[1] and increased by 2% when adjusted for China divestment. Net sales in North America grew by 1%[1] and, adjusted for Cimerli acquisition, by 3%","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Anticipated biosimilar launches primarily weighted to second half of year. Launches include Wyost®/Jubbonti® (denosumab) in Europe and US, Tyruko® (natalizumab) in US[2] and Afqlir® (aflibercept) in Europe","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable moves towards regulatory streamlining of biosimilar development reflected in decision to minimize pembrolizumab Phase III trial","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Full-year impact of US government’s confirmed recent tariffs within guidance","length":76,"tagName":"p"}]...